Bivictrix Therapeutics PLC - Macclesfield, England-based biotechnology company focused on cancer therapies - Says final sequences have been selected for its second programme BVX002, an antibody drug conjugate or ADC targeting solid tumour indications. Emerging data identifies high-grade serous ovarian cancer as one of the lead indications. Company says it is on track to identify the development lead in 2024. Says findings represent "significant unmet need and commercial potential for BVX002".
Chief Executive Officer Tiffany Thorn says: "ADCs have demonstrated incredible promise as an alternative therapeutic option to current monotherapies and combination therapies across difficult-to-treat cancers, backed by high specificity, versatility and selectivity. We have been encouraged by BiVictriX's progress to date in our lead BVX001 programme for the treatment of Acute Myeloid Leukaemia and are also pleased by the further development and expansion of our proprietary ADC pipeline."
Current stock price: 11.25 pence, up 2.3% in London on Thursday
12-month change: down 25%
By Emma Curzon, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
BiVictrix Therapeutics (BVX)